Loading...
XSHE
300119
Market cap1.26bUSD
Dec 05, Last price  
19.23CNY
1D
-0.21%
1Q
-11.10%
Jan 2017
11.87%
IPO
39.82%
Name

Tianjin Ringpu Bio-Technology Co Ltd

Chart & Performance

D1W1MN
XSHE:300119 chart
P/E
29.72
P/S
2.91
EPS
0.65
Div Yield, %
2.08%
Shrs. gr., 5y
3.00%
Rev. gr., 5y
15.92%
Revenues
3.07b
+36.50%
146,100,179224,133,644285,355,542345,619,033587,713,347656,393,897754,904,372585,196,983792,834,473969,858,4931,047,334,4881,189,866,0121,466,580,5042,000,407,1062,007,138,3042,084,250,3992,248,962,0533,069,933,116
Net income
301m
-33.61%
36,961,96043,321,87561,500,93182,539,811114,094,687144,079,002151,958,90327,128,623110,310,755132,782,489104,895,236118,978,853194,359,933398,196,538412,784,534346,698,684452,942,064300,722,269
CFO
736m
+94.49%
19,145,45868,072,29564,590,619112,815,21190,285,52289,918,33188,684,156128,370,937225,265,709207,668,427107,573,523174,881,770383,608,950388,439,470382,628,909389,486,980378,196,328735,546,207
Dividend
May 15, 20240.4 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sales of veterinary biological products, veterinary drug preparations, functional additives, and veterinary raw materials in China. The company provides vaccines and drugs for poultry, swine, and other animals; pet products comprising pet rabies inactivated vaccine, recombinant canine-a interferon, inhalation anesthetics isoflurane and sevoflurane for dogs and cats, cefquinoxime sulfate for injection for prevention and treatment of pet bacterial diseases, heart disease drugs for dogs and cats, napril chewable tablets and other products; and waterfowl products, including duck tempusu live/inactivated vaccine, gosling plague refined egg yolk antibody, duck infectious serositis inactivated vaccine, duck viral hepatitis refined egg yolk antibody, duck plague live vaccine, florfenicol soluble powder, kanamycin injection, etc. It also offers antifungal products, such as natural plant extracts, immune polysaccharides, clostridium butyricum, lactobacillus plantarum, antibacterial peptides, enzyme preparations, acidulants, etc; disinfection and cleaning products, consisting of potassium hydrogen persulfate composite powder, benzyl trimethyl ammonium chloride solution, deca methyl ammonium bromide solution, sodium dichloroisocyanurate, iodine glycerin solution, etc.; and APIs comprising tilmicosin, tilmicosin phosphate, monbutone, tidiroxine, florfenicol, vonimulin hydrochloride, gamimycin, etc. The company was founded in 1998 and is based in Tianjin, China.
IPO date
Sep 17, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT